Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/03/2023 | 23.11% | UBS | $155 → $160 | Maintains | Buy |
08/23/2023 | 7.72% | Goldman Sachs | $158 → $140 | Maintains | Neutral |
08/22/2023 | 7.72% | Goldman Sachs | $158 → $140 | Downgrades | Buy → Neutral |
07/27/2023 | 17.72% | Morgan Stanley | $153 → $153 | Reiterates | Overweight → Overweight |
07/12/2023 | 17.72% | Morgan Stanley | $128 → $153 | Maintains | Overweight |
04/27/2023 | 5.41% | Keefe, Bruyette & Woods | $135 → $137 | Maintains | Outperform |
04/27/2023 | -1.52% | Morgan Stanley | $131 → $128 | Maintains | Overweight |
04/12/2023 | 0.79% | Morgan Stanley | $102 → $131 | Upgrades | Equal-Weight → Overweight |
04/12/2023 | — | UBS | Upgrades | Sell → Buy | |
02/06/2023 | -21.52% | Morgan Stanley | $94 → $102 | Maintains | Equal-Weight |
02/02/2023 | 5.41% | Keefe, Bruyette & Woods | $132.5 → $137 | Maintains | Outperform |
01/12/2023 | -27.68% | Morgan Stanley | $87 → $94 | Maintains | Equal-Weight |
01/11/2023 | -3.82% | Goldman Sachs | $105 → $125 | Upgrades | Neutral → Buy |
01/09/2023 | -26.91% | UBS | $90 → $95 | Maintains | Sell |
10/27/2022 | -22.29% | Goldman Sachs | $90 → $101 | Maintains | Neutral |
10/27/2022 | -16.13% | Keefe, Bruyette & Woods | $106 → $109 | Downgrades | Outperform → Market Perform |
09/23/2022 | -34.6% | Evercore ISI Group | $99 → $85 | Downgrades | Neutral → Sell |
08/01/2022 | -23.83% | UBS | $104 → $99 | Maintains | Neutral |
07/19/2022 | -25.37% | Morgan Stanley | $136 → $97 | Maintains | Equal-Weight |
07/13/2022 | -28.45% | Goldman Sachs | $111 → $93 | Maintains | Neutral |
07/08/2022 | -9.21% | Piper Sandler | $142 → $118 | Maintains | Overweight |
04/07/2022 | 9.26% | Piper Sandler | $161 → $142 | Maintains | Overweight |
03/09/2022 | 23.87% | Piper Sandler | $180 → $161 | Maintains | Overweight |
03/08/2022 | 4.64% | Morgan Stanley | $156 → $136 | Maintains | Equal-Weight |
01/06/2022 | 8.49% | Goldman Sachs | $176 → $141 | Downgrades | Buy → Neutral |
01/04/2022 | 13.87% | UBS | $155 → $148 | Maintains | Neutral |
12/08/2021 | 20.03% | Morgan Stanley | $180 → $156 | Downgrades | Overweight → Equal-Weight |
11/04/2021 | 19.26% | UBS | $148 → $155 | Downgrades | Buy → Neutral |
10/11/2021 | 29.26% | Morgan Stanley | $160 → $168 | Maintains | Overweight |
04/09/2021 | — | JMP Securities | Downgrades | Outperform → Market Perform | |
04/07/2021 | 23.11% | Morgan Stanley | $155 → $160 | Maintains | Overweight |
04/01/2021 | 11.56% | UBS | $132 → $145 | Maintains | Buy |
03/19/2021 | 24.64% | Goldman Sachs | $139 → $162 | Upgrades | Buy → Conviction Buy |
03/12/2021 | 19.26% | Morgan Stanley | $144 → $155 | Maintains | Overweight |
02/04/2021 | 10.79% | Morgan Stanley | $135 → $144 | Maintains | Overweight |
12/16/2020 | -3.82% | Seaport Global | → $125 | Initiates Coverage On | → Buy |
12/14/2020 | 3.87% | Morgan Stanley | $102 → $135 | Maintains | Overweight |
12/01/2020 | — | Keefe, Bruyette & Woods | Upgrades | Market Perform → Outperform | |
10/12/2020 | -21.52% | Morgan Stanley | $66 → $102 | Maintains | Overweight |
10/09/2020 | -21.52% | JMP Securities | $83 → $102 | Maintains | Market Outperform |
10/02/2020 | -40.76% | UBS | → $77 | Upgrades | Neutral → Buy |
08/05/2020 | -50.76% | Goldman Sachs | $60 → $64 | Upgrades | Neutral → Buy |
07/23/2020 | -43.83% | Piper Sandler | $71 → $73 | Maintains | Overweight |
07/09/2020 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
04/23/2020 | -56.14% | Piper Sandler | $73 → $57 | Maintains | Overweight |
04/09/2020 | -36.14% | JMP Securities | $100 → $83 | Maintains | Market Outperform |
04/09/2020 | -49.22% | Morgan Stanley | $97 → $66 | Maintains | Overweight |
03/25/2020 | -66.15% | UBS | $79 → $44 | Maintains | Neutral |
01/13/2020 | -23.06% | JMP Securities | $105 → $100 | Maintains | Market Outperform |
01/06/2020 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
11/25/2019 | -26.14% | Morgan Stanley | → $96 | Initiates Coverage On | → Overweight |
11/20/2019 | -26.14% | Morgan Stanley | → $96 | Initiates Coverage On | → Overweight |
11/04/2019 | -37.68% | UBS | $89 → $81 | Maintains | Neutral |
08/14/2019 | -31.52% | Goldman Sachs | $84 → $89 | Upgrades | Sell → Neutral |
05/23/2019 | — | JMP Securities | Upgrades | Market Perform → Market Outperform | |
05/23/2019 | — | JMP Securities | Upgrades | Market Perform → Market Outperform | |
01/07/2019 | -49.22% | Goldman Sachs | $93 → $66 | Downgrades | Neutral → Sell |
11/06/2018 | -28.45% | Goldman Sachs | → $93 | Initiates Coverage On | → Neutral |
10/08/2018 | -17.67% | UBS | $117 → $107 | Maintains | Neutral |
What is the target price for Evercore (EVR)?
The latest price target for Evercore (NYSE: EVR) was reported by UBS on October 3, 2023. The analyst firm set a price target for $160.00 expecting EVR to rise to within 12 months (a possible 23.11% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evercore (EVR)?
The latest analyst rating for Evercore (NYSE: EVR) was provided by UBS, and Evercore maintained their buy rating.
When is the next analyst rating going to be posted or updated for Evercore (EVR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evercore, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evercore was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
Is the Analyst Rating Evercore (EVR) correct?
While ratings are subjective and will change, the latest Evercore (EVR) rating was a maintained with a price target of $155.00 to $160.00. The current price Evercore (EVR) is trading at is $129.97, which is out of the analyst's predicted range.